MetaVia rises after securing global patent protection for obesity drug
Brief: Metavia Inc - Announces Positive Ai-Modeling Results From Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets For Vanoglipel
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Brief: Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile
Brief: Metavia Regains Compliance With Nasdaq Minimum Bid Price Requirement
NASDAQ RESUMED AT 11:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:56 AM
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Metavia Inc. Announces 1-For-11 Reverse Stock Split
MetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Metavia Reports Second Quarter 2025 Financial Results And Provides Corporate Update
Brief: Metavia Extends 48 Mg MAD Portion Of Its Phase 1 Clinical Trial Of Da-1726 For Treatment Of Obesity
Brief: Metavia Announces Ai-Driven Collaboration With Syntekabio To Explore Additional Indications For Da-1241
Brief: Metavia Files For Resale Of Up To 14.1 Million Shares Of Common Stock By Selling Securityholders
Brief: Metavia Presents Pre-Clinical Data On Da-1241 Demonstrating Additive Hepatoprotective Effects In Combination With Efruxifermin At The ADA's 85Th Scientific Session